Research identifies potential new treatment for sepsis

Key points
- Sepsis is the leading cause of in-hospital death and there is no specific treatment for it.
- Sepsis is caused by an overwhelming immune response to an existing infection.
- Annexin A5 is a lipid-binding protein produced by cells.
- "We treated the septic animals and to our surprise we found a dramatic, significant effect in improving cardiac function during sepsis and improved survival rates in the mice," says Dr.
Sepsis is the leading cause of in-hospital death and there is no specific treatment for it. Now, research led by Dr. Qingping Feng of Western University (London, Canada) suggests a protein called recombinant human annexin A5 may have therapeutic potential for the treatment of this disease. The paper is published in advance, online in Critical Care Medicine.
Sepsis is caused by an overwhelming immune response to an existing infection. It's estimated there are 18 million cases annually worldwide. The mortality rate is 30 to 40 per cent for severe sepsis and 40 to 80 per cent for septic shock. Dr. Feng, a professor in the Departments of Physiology and Pharmacology, and Medicine at Western's Schulich School of Medicine & Dentistry and a scientist at Lawson Health Research Institute is particularly interested in how sepsis causes cardiac dysfunction.
Annexin A5 is a lipid-binding protein produced by cells. Using mice with induced sepsis, Dr. Feng, Dr. Xiangru Lu, and Paul Arnold, MSc, studied the effects of annexin A5 on cardiac function and animal survival.
"We treated the septic animals and to our surprise we found a dramatic, significant effect in improving cardiac function during sepsis and improved survival rates in the mice," says Dr. Feng. "We also found it helped even if administered hours after the septic infection. This is important because the delayed treatment simulates what usually happens in a clinical setting. The patient often has had sepsis for several hours, or a few days when they seek treatment."
Annexin A5 is not currently used as a therapeutic agent, but its safety has been tested in humans. It's currently used in imaging studies to identify cells undergoing apoptosis (cell death).
While this study looked at the heart, Dr. Feng believes annexin A5's beneficial properties could apply to multiple organs including liver, lungs and kidney, all which can all be affected by sepsis.
Treatment of severe sepsis will vary for each patient depending on the initial infection, the organs affected and the extent of damage.
If your sepsis is detected early enough and has not affected organ or tissue function (uncomplicated sepsis), it may be possible to treat the condition at home. You will be prescribed a course of antibiotic tablets.
If the sepsis is severe, or you develop septic shock, you will need emergency hospital treatment, usually in an intensive care unit (ICU). ICUs are able to support any affected body function, such as breathing or blood circulation, while the medical staff focus on treating the infection.
Antibiotics
Severe sepsis is treated with intravenous antibiotics (given directly into a vein). There will not usually be time to wait until a specific type of infection has been identified, so 'broad-spectrum' antibiotics will initially be given. Broad-spectrum antibiotics are designed to work against a wide range of known infectious bacteria, and can also treat some fungal infections.
Written and revised by
Andrey Nailor, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Infections, HIV & STIs →
NewsHIV discovery - biomarkers predict virus return when treatment is stopped
Scientists are now better able to predict how quickly the HIV virus will return after individuals stop treatment following a discovery by researchers at UNSW Australia and the University of Oxford. The significant…
10 October 2015
NewsFuture of HIV cure research points to combination approach
The next five years of HIV research should shift gears from the classic single-therapy development model to moving directly from in vitro studies to combination therapy trials, authors argue in a new paper published…
25 September 2015
NewsUCLA research offers more evidence for possible link between cocaine use and HIV infection
New UCLA research offers further evidence that cocaine use disrupts the immune system, making people who use it more likely to become infected with HIV. In research published online June 18 in the peer-reviewed journal…


